NBI-98854: Phase II started

Neurocrine began a double-blind, placebo-controlled, U.S. Phase II T-Forward trial to evaluate 2 dose levels of oral NBI-98854 once daily for 8 weeks in up to 90 patients with moderate to severe Toure...